Bicara Therapeutics (BCAX) Competitors $16.26 -1.99 (-10.90%) Closing price 04:00 PM EasternExtended Trading$16.22 -0.05 (-0.28%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAX vs. LNTH, MIRM, ADMA, ACAD, TLX, CGON, ZLAB, QURE, AAPG, and SRRKShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Lantheus (LNTH), Mirum Pharmaceuticals (MIRM), ADMA Biologics (ADMA), ACADIA Pharmaceuticals (ACAD), Telix Pharmaceuticals (TLX), CG Oncology (CGON), Zai Lab (ZLAB), uniQure (QURE), Ascentage Pharma Group International (AAPG), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors Lantheus Mirum Pharmaceuticals ADMA Biologics ACADIA Pharmaceuticals Telix Pharmaceuticals CG Oncology Zai Lab uniQure Ascentage Pharma Group International Scholar Rock Bicara Therapeutics (NASDAQ:BCAX) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Does the media prefer BCAX or LNTH? In the previous week, Lantheus had 26 more articles in the media than Bicara Therapeutics. MarketBeat recorded 40 mentions for Lantheus and 14 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.36 beat Lantheus' score of 0.05 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 5 Very Positive mention(s) 2 Positive mention(s) 26 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of BCAX or LNTH? 99.1% of Lantheus shares are owned by institutional investors. 2.0% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate BCAX or LNTH? Bicara Therapeutics currently has a consensus target price of $31.86, indicating a potential upside of 95.93%. Lantheus has a consensus target price of $74.50, indicating a potential upside of 31.63%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Bicara Therapeutics is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75Lantheus 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is BCAX or LNTH more profitable? Lantheus has a net margin of 17.82% compared to Bicara Therapeutics' net margin of 0.00%. Lantheus' return on equity of 34.06% beat Bicara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A -21.67% -20.89% Lantheus 17.82%34.06%19.10% Which has higher earnings & valuation, BCAX or LNTH? Lantheus has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/A-$68M-$3.17-5.13Lantheus$1.53B2.51$312.44M$3.7615.05 SummaryLantheus beats Bicara Therapeutics on 10 of the 15 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$887.96M$3.46B$6.17B$10.68BDividend YieldN/A2.27%5.72%4.83%P/E Ratio-5.1323.2129.4127.38Price / SalesN/A479.02588.00132.78Price / CashN/A45.2825.8230.35Price / Book1.8010.5412.496.68Net Income-$68M-$52.62M$3.32B$276.27M7 Day Performance-12.16%4.90%2.38%0.95%1 Month Performance55.75%15.97%8.71%3.92%1 Year Performance-25.96%14.17%61.90%36.33% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics2.4665 of 5 stars$16.26-10.9%$31.86+95.9%-16.9%$887.96MN/A-5.1332Gap DownHigh Trading VolumeLNTHLantheus4.5846 of 5 stars$54.71+0.2%$74.50+36.2%-52.4%$3.72B$1.53B14.54700MIRMMirum Pharmaceuticals3.7878 of 5 stars$72.81+0.9%$76.50+5.1%+86.3%$3.66B$336.89M-60.16140Analyst RevisionADMAADMA Biologics3.6629 of 5 stars$15.21+4.5%$27.67+81.9%-9.0%$3.63B$426.45M17.67530ACADACADIA Pharmaceuticals3.8944 of 5 stars$20.04-0.1%$29.12+45.3%+36.5%$3.38B$957.80M15.08510Gap UpTLXTelix Pharmaceuticals3.8291 of 5 stars$9.84+3.2%$21.00+113.3%N/A$3.33B$516.72M0.00N/AGap UpCGONCG Oncology1.7772 of 5 stars$42.85-0.3%$58.82+37.3%+13.8%$3.27B$1.14M-24.2361ZLABZai Lab2.6397 of 5 stars$29.07-6.9%$56.35+93.9%+2.9%$3.25B$398.99M-14.261,869Gap UpQUREuniQure2.0665 of 5 stars$58.71-5.3%$71.75+22.2%+803.4%$3.24B$27.12M-15.07500Gap UpAAPGAscentage Pharma Group InternationalN/A$34.28-6.0%N/AN/A$3.19B$390.60M0.00600SRRKScholar Rock4.5184 of 5 stars$33.03-3.7%$48.60+47.2%-8.5%$3.18B$33.19M-11.38140Analyst ForecastGap Down Related Companies and Tools Related Companies LNTH Competitors MIRM Competitors ADMA Competitors ACAD Competitors TLX Competitors CGON Competitors ZLAB Competitors QURE Competitors AAPG Competitors SRRK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
